Democratizing Generative AI: Copilots In The Biopharma Industry
Learn how AI co-pilots revolutionize the biopharma industry, solving specific use-cases efficiently. Discover how Flight Deck software democratizes...
Discover what three prominent CEOs predict for the biopharma industry in 2024 and reflect on the groundbreaking advancements of 2023.
The year 2023 marked significant advancements in biopharma, with notable milestones such as the approval of the Alzheimer’s disease drug Leqembi and the first CRISPR-edited therapy.
As we reflect on these pivotal moments and anticipate what 2024 holds, GEN engaged CEOs from three prominent companies—Zevra Therapeutics, Axogen, and Ryght—to share insights on the broader industry landscape and their respective company strategies.
Neil McFarlane of Zevra highlights the company's recent acquisition and its progress towards treating Niemann-Pick disease type C. Karen Zaderej from Axogen discusses the company's growth trajectory and the launch of innovative nerve products.
Simon Arkell of Ryght delves into the company's generative AI platform to enhance biopharma decision-making.
Read the full article here on genengnews.com
